Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

March 25, 2025

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

DCAT Week 2025: Key Ingredients in Pharmaceutical Manufacturing

March 19, 2025

Roquette Pharma Solutions' Christine Mya-San, global account manager, highlights the most significant pharma ingredients at play over the past year and discusses future ingredient innovation.

International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma

March 08, 2025

In an interview with Pharmaceutical Technology®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.

FDA Approves Evrysdi Tablet from Roche for Spinal Muscular Atrophy

February 17, 2025

The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.

Next-Generation Anti-Obesity Medicines

February 08, 2025

European biopharma companies are looking beyond GLP-1s.

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

January 15, 2025

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

January 07, 2025

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

January 04, 2025

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.

Orexo and Abera Partner to Develop Nasal Powder Vaccines

December 20, 2024

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

December 10, 2024

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.